-
Switch 2 sales boost Nintendo results but chip shortage looms
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Russia resumes strikes on freezing Ukrainian capital
-
'Way too far': Latino Trump voters shocked by Minneapolis crackdown
-
England and Brook seek redemption at T20 World Cup
-
Coach Gambhir under pressure as India aim for back-to-back T20 triumphs
-
'Helmets off': NFL stars open up as Super Bowl circus begins
-
Japan coach Jones says 'fair' World Cup schedule helps small teams
-
Do not write Ireland off as a rugby force, says ex-prop Ross
-
Winter Olympics 2026: AFP guide to Alpine Skiing races
-
Winter Olympics to showcase Italian venues and global tensions
-
Buoyant England eager to end Franco-Irish grip on Six Nations
-
China to ban hidden car door handles in industry shift
-
Sengun leads Rockets past Pacers, Ball leads Hornets fightback
-
Waymo raises $16 bn to fuel global robotaxi expansion
-
Netflix to livestream BTS comeback concert in K-pop mega event
-
Rural India powers global AI models
-
Equities, metals, oil rebound after Asia-wide rout
-
Bencic, Svitolina make history as mothers inside tennis top 10
-
Italy's spread-out Olympics face transport challenge
-
Son of Norway crown princess stands trial for multiple rapes
-
Side hustle: Part-time refs take charge of Super Bowl
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Faced with Trump, Pope Leo opts for indirect diplomacy
-
NFL chief expects Bad Bunny to unite Super Bowl audience
-
Australia's Hazlewood to miss start of T20 World Cup
-
Bill, Hillary Clinton to testify in US House Epstein probe
-
Cuba confirms 'communications' with US, but says no negotiations yet
-
From 'watch his ass' to White House talks for Trump and Petro
-
Trump says not 'ripping' down Kennedy Center -- much
-
Sunderland rout 'childish' Burnley
-
Musk merges xAI into SpaceX in bid to build space data centers
-
Former France striker Benzema switches Saudi clubs
-
Sunderland rout hapless Burnley
-
Costa Rican president-elect looks to Bukele for help against crime
-
Hosts Australia to open Rugby World Cup against Hong Kong
-
New York records 13 cold-related deaths since late January
-
In post-Maduro Venezuela, pro- and anti-government workers march for better pay
-
Romero slams 'disgraceful' Spurs squad depth
-
Trump says India, US strike trade deal
-
Cuban tourism in crisis; visitors repelled by fuel, power shortages
-
Liverpool set for Jacquet deal, Palace sign Strand Larsen on deadline day
-
FIFA president Infantino defends giving peace prize to Trump
-
Trump cuts India tariffs, says Modi will stop buying Russian oil
-
Borthwick backs Itoje to get 'big roar' off the bench against Wales
-
Twenty-one friends from Belgian village win €123mn jackpot
-
Mateta move to Milan scuppered by medical concerns: source
-
Late-January US snowstorm wasn't historically exceptional: NOAA
-
Punctuality at Germany's crisis-hit railway slumps
-
Halt to MSF work will be 'catastrophic' for people of Gaza: MSF chief
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
E.Ramalho--PC